Search Results

You are looking at 201 - 210 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Abstracts From the NCCN 2022 Annual Conference

Trial of Concurrent Nab-Paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer Ping Jiang, PhD 1 ; Ang Qu, PhD 1 ; Weijuan Jiang, PhD 1 ; Xiuwen Deng, PhD 1 ; Junjie Wang, PhD 1 1 Peking University Third Hospital, Beijing

Full access

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes

first-line systemic therapy. Alectinib is a preferred option if an ALK rearrangement is discovered during first-line systemic therapy (eg, carboplatin/[pemetrexed or paclitaxel]). Brigatinib, ceritinib, crizotinib, and lorlatinib are also recommended

Full access

Computed Tomography Screening for the Early Detection of Lung Cancer

Rebecca P. Petersen and David H. Harpole Jr.

. 18. Strauss GA Herndon JE Maddaus MA . Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol

Full access

Myeloid Growth Factor Therapy for Prophylaxis of Febrile Neutropenia in Non-Myeloid Malignancies: Appropriate Doses and Schedules

Betsy L. Althaus

increasing dose intensity . Am J Clin Oncol 1999 ; 22 : 38 – 41 . 22. Livingston RB Ellis GK Gralow JR . Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

Full access

Clinical Trials: Does One Size Really Fit All?

Margaret Tempero

metastatic to liver. He asked if we had a clinical trial he could participate in. I explained that we did, but that the chemotherapy backbone of the trial was gemcitabine and albumin-bound paclitaxel. Given the BRCA1 mutation, he had a higher likelihood of

Full access

It’s About Time!

Margaret Tempero

Compared with other malignancies, the treatment landscape for pancreatic cancer is pretty sparse. The last 2 drug approvals occurred several years ago and both drugs (albumin-bound paclitaxel and liposomal irinotecan) were formulated for better

Full access

Five Patients and One Important Lesson

Margaret Tempero

FOLFIRINOX or gemcitabine and nab-paclitaxel until 2010 or later. Talk about slow progress! Most of the patients I see will die of this disease. We can prolong their lives, but it is a temporary reprieve. Invariably, when I see a new patient, he or she

Full access

The Role of Cytoreductive/Debulking Surgery in Ovarian Cancer

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

debulking surgery . J Surg Oncol 1991 ; 48 : 39 – 44 . 4. McGuire WP Hoskins WJ Brady MF . Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996

Full access

Access to and Appropriateness of Cancer Care: Who Decides?

William T. McGivney

paclitaxel in combination be a treatment option for women with metastatic breast cancer. The vote of the NCCN Guidelines Panel on this issue was 15 to 0. The European Medicines Agency, the counterpart of the FDA for the European Union, has adopted a position

Full access

NCCN Guidelines Updates: Breast Cancer

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

single standard treatment exists for patients with small, node-negative, HER2-positive breast cancers, but there is evidence that chemotherapy might be useful in some. Tolaney et al 3 conducted a study of adjuvant paclitaxel (given weekly for 12 weeks